![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07K2317/76 | (2013.01) |
C07K 16/28 | (2006.01) | ||
C07K 16/30 | (2006.01) | ||
C07K2317/92 | (2013.01) | ||
A61K 39/395 | (2006.01) | ||
C07K2317/74 | (2013.01) | ||
G01N 33/566 | (2013.01) | ||
G01N 33/6854 | (2013.01) | ||
A61K 45/06 | (2013.01) | ||
C07K 16/30 | (2013.01) | ||
C07K2317/24 | (2013.01) | ||
C07K 16/2818 | (2013.01) | ||
A61P 1/04 | (2018.01) | ||
A61P 1/16 | (2018.01) | ||
A61P 1/18 | (2018.01) | ||
A61P 11/00 | (2018.01) | ||
A61P 13/08 | (2018.01) | ||
A61P 13/12 | (2018.01) | ||
A61P 15/00 | (2018.01) | ||
A61P 17/00 | (2018.01) | ||
A61K 39/3955 | (2013.01) | ||
A61P 31/00 | (2018.01) | ||
A61P 35/00 | (2018.01) | ||
A61P 35/02 | (2018.01) | ||
A61P 35/04 | (2018.01) | ||
A61P 37/02 | (2018.01) | ||
A61P 37/04 | (2018.01) | ||
A61P 43/00 | (2018.01) | ||
A61P 5/14 | (2018.01) | ||
A61P 7/00 | (2018.01) | ||
Y02A 50/30 | (2018.01) |
(11) | Number of the document | 3514179 |
(13) | Kind of document | T |
(96) | European patent application number | 18211373.8 |
Date of filing the European patent application | 2015-01-23 | |
(97) | Date of publication of the European application | 2019-07-24 |
(45) | Date of publication and mention of the grant of the patent | 2022-11-02 |
(46) | Date of publication of the claims translation |
(30) | Number | Date | Country code |
201461931512 P | 2014-01-24 | US | |
201462059676 P | 2014-10-03 | US | |
201462094834 P | 2014-12-19 | US |
(72) |
FREEMAN, Gordon, James , US
SHARPE, Arlene, Helen , US
BLATTLER, Walter, A. , US
MATARAZA, Jennifer, Marie , US
SABATOS-PEYTON, Catherine, Anne , US
CHANG, Hwai, Wen , US
FREY, Gerhard, Johann , US
|
(73) |
Dana-Farber Cancer Institute, Inc. ,
450 Brookline Avenue, Boston, MA 02115-5450,
US
Novartis AG , Lichtstrasse 35, 4056 Basel, CH President and Fellows of Harvard College , 17 Quincy Street, Cambridge, MA 02138, US |
(54) | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF |
ANTIBODY MOLECULES TO PD-1 AND USES THEREOF |